In this issue of Blood, Thompson et al present their exciting long-Term results with the use of fludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy in patients with previously untreated chronic lymphocytic leukemia (CLL).1.
|Original language||English (US)|
|Number of pages||1|
|State||Published - Jan 21 2016|
ASJC Scopus subject areas
- Cell Biology